A new mini-review outlines how hybrid and synthetic extracellular vesicle platforms are being engineered to address the core limitations of natural EVs, including low yield, heterogeneity, and limited controllability in drug delivery and theranostics. The authors describe platform design strategies intended to improve batch consistency and functional loading. As EV therapeutics move toward more clinical-grade manufacturing expectations, these engineering approaches are likely to influence how sponsors standardize characterization assays, potency measurement, and dosing reproducibility.